Destiny Pharma

Destiny Pharma initiates research to explore XF drug potential for CF

Study to investigate the potential of XF-73 to treat MRSA infection in people with cystic fibrosis 14 August 2024 — Brighton, UK — Destiny Pharma, a clinical stage biotechnology company focused on the development and commercialisation of novel medicines to prevent and cure life threatening infections, is pleased to announce the initiation of a research…

Cardiac surgery patients treated with XF-73 Nasal gel require significantly fewer post-surgical antibiotics

22 July 2024 – Brighton, United Kingdom – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development and commercialisation of novel medicines to prevent and cure life threatening infections, today announced that new clinical data from its phase 2b clinical trial on XF-73 in cardiac surgery patients has been accepted for…